Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 816730
                    [Title] => Efficacy results of Otsuka's delamanid for MDR-TB published in journal
                    [Summary] => 
An investigational compound for the treatment of multidrug-resistant tuberculosis (MDR-TB) was shown to be effective with a good safety profile in research spearheaded by global healthcare company Otsuka Pharmaceutical Co. Ltd. (Otsuka).
                    [DatePublished] => 2012-06-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 63596
                    [Title] => Study Shows: Generic anti-platelet agent not bioequivalent to innovator drug
                    [Summary] => 
            
                    [DatePublished] => 2008-05-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

OTSUKA PHARMACEUTICAL CO

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 816730
                    [Title] => Efficacy results of Otsuka's delamanid for MDR-TB published in journal
                    [Summary] => 
An investigational compound for the treatment of multidrug-resistant tuberculosis (MDR-TB) was shown to be effective with a good safety profile in research spearheaded by global healthcare company Otsuka Pharmaceutical Co. Ltd. (Otsuka).
                    [DatePublished] => 2012-06-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 63596
                    [Title] => Study Shows: Generic anti-platelet agent not bioequivalent to innovator drug
                    [Summary] => 
            
                    [DatePublished] => 2008-05-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Efficacy results of Otsuka's delamanid for MDR-TB published in journal

June 14, 2012 - 12:00am

An investigational compound for the treatment of multidrug-resistant tuberculosis (MDR-TB) was shown to be effective with a good safety profile in research spearheaded by global healthcare company Otsuka Pharmaceutical...

Science and Environment

Study Shows: Generic anti-platelet agent not bioequivalent to innovator drug

May 22, 2008 - 12:00am

Science and Environment